Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03937830 |
|---|---|
| Brief Title: | Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma |
| First Submitted : | May 3, 2019 |
| First Submitted that Met QC Criteria : | May 3, 2019 |
| First Posted : | May 6, 2019 |
| Last Update Submitted that Met QC Criteria : | May 14, 2024 |
| Last Update Posted : | May 16, 2024 |